Shares of Biopharmx Corp (NASDAQ:BPMX) have been given an average broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy rating.

Brokerages have set a twelve-month consensus target price of $3.38 for the company and are forecasting that the company will post ($0.07) earnings per share for the current quarter, according to Zacks. Zacks has also given Biopharmx Corp an industry rank of 110 out of 265 based on the ratings given to its competitors.

BPMX has been the topic of several research analyst reports. HC Wainwright set a $3.00 target price on Biopharmx Corp and gave the company a “buy” rating in a research note on Thursday, June 15th. Roth Capital set a $3.00 target price on Biopharmx Corp and gave the company a “buy” rating in a research note on Saturday, June 3rd. Finally, Maxim Group reissued a “buy” rating and set a $3.00 target price on shares of Biopharmx Corp in a research note on Friday, June 2nd.

TRADEMARK VIOLATION NOTICE: “Zacks: Biopharmx Corp (BPMX) Given $3.38 Consensus Target Price by Analysts” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another site, it was copied illegally and reposted in violation of international copyright and trademark laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/09/09/zacks-biopharmx-corp-bpmx-given-3-38-consensus-target-price-by-analysts.html.

Shares of Biopharmx Corp (NASDAQ BPMX) opened at 0.34 on Friday. The stock’s 50 day moving average is $0.31 and its 200 day moving average is $0.48. Biopharmx Corp has a 12 month low of $0.19 and a 12 month high of $0.90. The firm’s market cap is $25.20 million.

Biopharmx Corp (NASDAQ:BPMX) last posted its earnings results on Tuesday, June 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.07). Biopharmx Corp had a negative return on equity of 1,847.04% and a negative net margin of 28,405.26%. The firm had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.03 million. Equities research analysts expect that Biopharmx Corp will post ($0.31) EPS for the current year.

In other Biopharmx Corp news, major shareholder Franklin Resources Inc bought 250,000 shares of Biopharmx Corp stock in a transaction dated Tuesday, August 1st. The shares were purchased at an average cost of $0.34 per share, with a total value of $85,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

A number of hedge funds have recently modified their holdings of the stock. Virtu KCG Holdings LLC grew its stake in Biopharmx Corp by 366.2% in the second quarter. Virtu KCG Holdings LLC now owns 503,418 shares of the company’s stock worth $241,000 after purchasing an additional 395,424 shares during the period. Vivo Capital LLC grew its stake in Biopharmx Corp by 10.0% in the second quarter. Vivo Capital LLC now owns 14,096,338 shares of the company’s stock worth $6,752,000 after purchasing an additional 1,282,052 shares during the period. Finally, Vanguard Group Inc. grew its stake in Biopharmx Corp by 324.6% in the second quarter. Vanguard Group Inc. now owns 1,933,747 shares of the company’s stock worth $927,000 after purchasing an additional 1,478,338 shares during the period.

Biopharmx Corp Company Profile

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

Get a free copy of the Zacks research report on Biopharmx Corp (BPMX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with MarketBeat.com's FREE daily email newsletter.